---
title: "Pomerantz LLP Advises Shareholders of Class Action Against Lantheus Holdings, Inc. – LNTH"
description: "Pomerantz LLP has announced a class action lawsuit against Lantheus Holdings, Inc. for alleged securities fraud and unlawful business practices. Shareholders who purchased Lantheus securities during t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263859649.md"
published_at: "2025-11-01T15:00:02.000Z"
---

# Pomerantz LLP Advises Shareholders of Class Action Against Lantheus Holdings, Inc. – LNTH

> Pomerantz LLP has announced a class action lawsuit against Lantheus Holdings, Inc. for alleged securities fraud and unlawful business practices. Shareholders who purchased Lantheus securities during the Class Period can contact Pomerantz to join the lawsuit by November 10, 2025. The lawsuit follows disappointing financial results for Lantheus, including significant stock price declines after the company reported lower-than-expected sales for its oncology product, Pylarify, and reduced growth projections.

NEW YORK CITY, NY / ACCESS Newswire / November 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. ("Lantheus" or the "Company") . Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether Lantheus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

You have until November 10, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Lantheus securities during the Class Period. A copy of the Complaint can be obtained at **www.pomerantzlaw.com****.**

\[Click here for information about joining the class action\]

On May 7, 2025, Lantheus reported its financial results for the first quarter of 2025, which fell short of market expectations. Lantheus announced, among other items, that sales of its radiopharmaceutical oncology product Pylarify had decreased year-over-year due to an alleged "temporal competitive disruption." The Company further reduced its previous full-year projections due to Pylarify's shortfall.

On this news, Lantheus's stock price fell $24.35 per share, or 23.23%, to close at $80.49 per share on May 7, 2025.

Then, on August 6, 2026, Lantheus announced disappointing second quarter 2025 results, revealing earnings-per-share ("EPS") and revenue figures that missed expectations. Once again, Lantheus significantly lowered growth expectations for Pylarify, sales of which had fallen 8.3% year-over-year, and further lowered the Company's full-year 2025 projections. Lantheus attributed its results in part to ongoing competition, which impacted Pylarify's pricing dynamics.

On this news, Lantheus's stock price fell $20.76 per share, or 28.58%, to close at $51.87 per share on August 6, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

**SOURCE:** Pomerantz LLP

View the original press release on ACCESS Newswire

### Related Stocks

- [LNTH.US - Lantheus](https://longbridge.com/en/quote/LNTH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 简讯——据彭博新闻报道，数字银行 Maya 正在考虑在美国进行规模高达 10 亿美元的首次公开募股 | 2 月 16 日（路透社）- * 据彭博社报道，数字银行 Maya 正在考虑进行高达 10 亿美元的美国首次公开募股（IPO）- 来源文本：进一步的公司报道：[ ] | [Link](https://longbridge.com/en/news/276039136.md) |
| ETDOOR 投资者有机会主导美森耐特国际公司证券欺诈诉讼 | 罗森律师事务所宣布对在 2023 年 6 月 5 日至 2024 年 2 月 8 日期间出售梅森国际公司（NYSE: DOOR）普通股的投资者提起集体诉讼。投资者可能有权获得赔偿，无需预付费用。诉讼指控在欧文斯科宁收购梅森股票的提议中存在重 | [Link](https://longbridge.com/en/news/276086471.md) |
| 19:16 ET Pom 投资者有机会主导对 PomDoctor Ltd.的证券欺诈诉讼 | 罗森律师事务所已宣布对 PomDoctor Ltd.（纳斯达克代码：POM）投资者提起集体诉讼，涉及购买证券的时间为 2025 年 10 月 9 日至 2025 年 12 月 11 日。投资者可能有权获得赔偿，无需预付费用。诉讼指控 Pom | [Link](https://longbridge.com/en/news/275826590.md) |
| uniQure N.V.的投资者有机会主导证券欺诈诉讼 | 罗森律师事务所已宣布对在 2025 年 9 月 24 日至 2025 年 10 月 31 日期间购买 uniQure N.V.（NASDAQ: QURE）股票的投资者提起集体诉讼。投资者可能有权获得无需预付费用的赔偿。诉讼声称 uniQur | [Link](https://longbridge.com/en/news/276158425.md) |
| $HUBG 法律通知：枢纽集团公司因财务重述面临证券欺诈调查 | Hub Group Inc. 正在接受 Bleichmar Fonti & Auld LLP 的调查，原因是可能违反了与财务重述相关的联邦证券法。此次调查是在 Hub Group 于 2026 年 2 月 5 日宣布将推迟发布 2025 年 | [Link](https://longbridge.com/en/news/275940584.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.